← Leaderboards
Mark R. Kelley
Indiana Univ-Purdue Univ At Indianapolis
$16,203,613
Attributed
$23,415,442
Total exposure
16
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.3M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$23,415,442 · 16
By mechanism
R01$19,636,842 · 9
P30$2,419,416 · 3
T32$464,798 · 1
R21$429,000 · 1
R43$240,322 · 1
R41$225,064 · 1
Top collaborators
- Melissa L Fishel17 shared
- Jill C Fehrenbacher10 shared
- Timothy W Corson4 shared
- David W. Clapp3 shared
- Martin F Haslanger2 shared
- Michael R Vasko2 shared
- Xiaoxi Qiao1 shared
Most similar at Indiana Univ-Purdue Univ At Indianapolis
Same institution · by research overlap
- Lawrence Lumeng$7,236,538
- Melissa L Fishel$7,092,542
- Paula J Bice$1,881,357
- Michael R Vasko$4,632,489
- Dawn Patricia Gail Fitzpatrick$5,992
Others in their field
Top investigators on “Oxidation-Reduction”
- Stuart A Lipton · Burnham Institute For Medical Research$22,352,588
- Yvonne M.w. Janssen-Heininger · University Of Vermont &St Agric College$16,004,795
- Joshua N. Adkins · Battelle Pacific Northwest Laboratories$14,698,503
- Stephen W Ragsdale · University Of Nebraska Lincoln$13,916,230
- Vadim N. Gladyshev · University Of Nebraska Lincoln$13,299,162
- Andres Vazquez-Torres · Va Eastern Colorado Health Care System$12,422,594
Research focus
Oxidation-ReductionPharmaceutical PreparationsProteinsDna RepairTranscription FactorBaseCellsPathway InteractionsMalignant NeoplasmsIn VivoMutantResponseEndonucleaseCancer TherapySignal TransductionPreventAntineoplastic AgentsChemotherapyIn VitroDna DamageTumorMediatingIn Vivo ModelMolecular Target
Grant awards (67)
Metabolic flux analysis and PDX models to understand therapeutic vulnerabilities following inhibition of Ref-1 redox signaling in pancreatic cancer$479,470
R01 · FY2025 · CA · contact PI
Pediatric and Adult Translational Cancer Drug Discovery and Development Training Program (PACT-D3)$141,457
T32 · FY2025 · CA · contact PI
Metabolic flux analysis and PDX models to understand therapeutic vulnerabilities following inhibition of Ref-1 redox signaling in pancreatic cancer$81,710
R01 · FY2025 · CA · contact PI
Metabolic flux analysis and PDX models to understand therapeutic vulnerabilities following inhibition of Ref-1 redox signaling in pancreatic cancer$443,001
R01 · FY2024 · CA · contact PI
Pediatric and Adult Translational Cancer Drug Discovery and Development Training Program (PACT-D3)$164,494
T32 · FY2024 · CA · contact PI
Metabolic flux analysis and PDX models to understand therapeutic vulnerabilities following inhibition of Ref-1 redox signaling in pancreatic cancer$75,358
R01 · FY2024 · CA · contact PI
Metabolic flux analysis and PDX models to understand therapeutic vulnerabilities following inhibition of Ref-1 redox signaling in pancreatic cancer$27,108
R01 · FY2024 · CA · contact PI
Metabolic flux analysis and PDX models to understand therapeutic vulnerabilities following inhibition of Ref-1 redox signaling in pancreatic cancer$466,315
R01 · FY2023 · CA · contact PI
Targeting the Ref-1 signaling node for treating ocular neovascularization$459,194
R01 · FY2023 · EY · contact PI
Developmental Funds$322,578
P30 · FY2023 · CA · contact PI
Pediatric and Adult Translational Cancer Drug Discovery and Development Training Program (PACT-D3)$158,847
T32 · FY2023 · CA · contact PI
Exploiting the Ref-1 node in pancreatic cancer: tailoring new pancreatic cancer therapy using multi-targeted combinations$483,852
R01 · FY2022 · CA · contact PI
(PQ12) Enhancement of DNA repair in neurons via a targeted APE1 small molecule modifier to decrease and reverse chemotherapy-induced peripheral neuropathy (CIPN)$451,597
R01 · FY2022 · CA
Targeting the Ref-1 signaling node for treating ocular neovascularization$445,418
R01 · FY2022 · EY
Developmental Funds$322,578
P30 · FY2022 · CA · contact PI
(PQ9)Mechanistic Role of APE1 and BER in chemotherapy-induced peripheral neuropathy$537,592
R01 · FY2021 · CA · contact PI
Exploiting the Ref-1 node in pancreatic cancer: tailoring new pancreatic cancer therapy using multi-targeted combinations$493,726
R01 · FY2021 · CA · contact PI
(PQ12) Enhancement of DNA repair in neurons via a targeted APE1 small molecule modifier to decrease and reverse chemotherapy-induced peripheral neuropathy (CIPN)$460,814
R01 · FY2021 · CA
Targeting the Ref-1 signaling node for treating ocular neovascularization$445,418
R01 · FY2021 · EY
Developmental Funds$322,578
P30 · FY2021 · CA · contact PI
(PQ9)Mechanistic Role of APE1 and BER in chemotherapy-induced peripheral neuropathy$537,592
R01 · FY2020 · CA · contact PI
Exploiting the Ref-1 node in pancreatic cancer: tailoring new pancreatic cancer therapy using multi-targeted combinations$493,726
R01 · FY2020 · CA · contact PI
(PQ12) Enhancement of DNA repair in neurons via a targeted APE1 small molecule modifier to decrease and reverse chemotherapy-induced peripheral neuropathy (CIPN)$460,814
R01 · FY2020 · CA
Targeting the Ref-1 signaling node for treating ocular neovascularization$374,878
R01 · FY2020 · EY
Developmental Funds$322,578
P30 · FY2020 · CA · contact PI
Exploiting the Ref-1 node in pancreatic cancer: tailoring new pancreatic cancer therapy using multi-targeted combinations$563,735
R01 · FY2019 · CA · contact PI
(PQ9)Mechanistic Role of APE1 and BER in chemotherapy-induced peripheral neuropathy$521,463
R01 · FY2019 · CA · contact PI
(PQ12) Enhancement of DNA repair in neurons via a targeted APE1 small molecule modifier to decrease and reverse chemotherapy-induced peripheral neuropathy (CIPN)$446,989
R01 · FY2019 · CA
Developmental Funds$322,578
P30 · FY2019 · CA · contact PI
(PQ9)Mechanistic Role of APE1 and BER in chemotherapy-induced peripheral neuropathy$537,592
R01 · FY2018 · CA · contact PI
Exploiting the Ref-1 node in pancreatic cancer: tailoring new pancreatic cancer therapy using multi-targeted combinations$493,726
R01 · FY2018 · CA · contact PI
(PQ12) Enhancement of DNA repair in neurons via a targeted APE1 small molecule modifier to decrease and reverse chemotherapy-induced peripheral neuropathy (CIPN)$460,814
R01 · FY2018 · CA
Exploiting the Ref-1 node in pancreatic cancer: tailoring new pancreatic cancer therapy using multi-targeted combinations$227,554
R01 · FY2018 · CA · contact PI
(PQ9)Mechanistic Role of APE1 and BER in chemotherapy-induced peripheral neuropathy$536,312
R01 · FY2017 · CA · contact PI
Novel Role of Ref-1 in Pancreatic Cancer Etiology and Progression$493,963
R01 · FY2017 · CA · contact PI
Novel Role of Ref-1 in Pancreatic Cancer Etiology and Progression$493,963
R01 · FY2016 · CA · contact PI
DNA damage and repair in inflammation-induced peripheral sensitization$195,000
R21 · FY2016 · NS
Novel Role of Ref-1 in Pancreatic Cancer Etiology and Progression$493,963
R01 · FY2015 · CA · contact PI
DNA damage and repair in inflammation-induced peripheral sensitization$234,000
R21 · FY2015 · NS
Novel Role of Ref-1 in Pancreatic Cancer Etiology and Progression$479,144
R01 · FY2014 · CA · contact PI
Novel Role of Ref-1 in Pancreatic Cancer Etiology and Progression$493,963
R01 · FY2013 · CA · contact PI
Novel Therapeutic Strategy for Refractory and Relapse Childhood Acute Leukemia$240,322
R43 · FY2013 · CA
The Role of Ape1 in Neurotoxicity of Cancer Treatments$405,107
R01 · FY2012 · CA · contact PI
The Role of Ape1 in Neurotoxicity of Cancer Treatments$403,464
R01 · FY2011 · CA · contact PI
The Role of Ape1 in Neurotoxicity of Cancer Treatments$414,074
R01 · FY2010 · CA · contact PI
The Role of Ape1 in Neurotoxicity of Cancer Treatments$404,126
R01 · FY2009 · CA · contact PI
The Role of Ape1 in Neurotoxicity of Cancer Treatments$358,757
R01 · FY2009 · CA · contact PI
Redox protein APE1/Ref-1 as a target for age-related macular degeneration (AMD)$225,064
R41 · FY2009 · EY
The Role of Ape1 in Neurotoxicity of Cancer Treatments$434,754
R01 · FY2008 · CA · contact PI
Imbalancing DNA BER to enhance Ovarian Tumor Sensitivity$285,864
R01 · FY2008 · CA · contact PI
Imbalancing DNA BER to enhance Ovarian Tumor Sensitivity$286,256
R01 · FY2007 · CA · contact PI
Therapeutic/Mechanistic Role of Ape1 in Germ Cell Tumors$208,737
R01 · FY2007 · CA · contact PI
Imbalancing DNA BER to enhance Ovarian Tumor Sensitivity$295,002
R01 · FY2006 · CA · contact PI
Therapeutic/Mechanistic Role of Ape1 in Germ Cell Tumors$214,971
R01 · FY2006 · CA · contact PI
Imbalancing DNA BER to enhance Ovarian Tumor Sensitivity$308,525
R01 · FY2005 · CA
Therapeutic/Mechanistic Role of Ape1 in Germ Cell Tumors$223,388
R01 · FY2005 · CA
Imbalancing DNA BER to enhance Ovarian Tumor Sensitivity$308,525
R01 · FY2004 · CA
Therapeutic/Mechanistic Role of Ape1 in Germ Cell Tumors$224,140
R01 · FY2004 · CA
OXIDATIVE DNA DAMAGE AND REPAIR IN CNS CELLS$324,200
R01 · FY2003 · NS
Therapeutic/Mechanistic Role of Ape1 in Germ Cell Tumors$235,376
R01 · FY2003 · CA
OXIDATIVE DNA DAMAGE AND REPAIR IN CNS CELLS$312,350
R01 · FY2002 · NS
CORE--CELL AND MOLECULAR BIOLOGY$228,564
P30 · FY2002 · DK
OXIDATIVE DNA DAMAGE AND REPAIR IN CNS CELLS$300,938
R01 · FY2001 · NS
CORE--CELL AND MOLECULAR BIOLOGY$228,564
P30 · FY2001 · DK
CORE--CELL AND MOLECULAR BIOLOGY$228,564
P30 · FY2001 · DK
OXIDATIVE DNA DAMAGE AND REPAIR IN CNS CELLS$227,524
R01 · FY2000 · NS
CORE--CELL AND MOLECULAR BIOLOGY$120,834
P30 · FY2000 · DK